3 Reasons To Buy Eli Lilly Now

Shares are down about 12% recently, but the stock remains a Buy on strategic catalysts and valuation upside. Near-term headwinds include Zepbound price cuts, slower revenue-growth guidance and acquisition-related earnings drag from the Centessa (CNTA) deal. Offsetting this, FDA approval of orforglipron and the Centessa acquisition expand Eli Lilly's cardio‑metabolic and neuroscience pipelines, supporting longer-term growth prospects.

Analysis

The market is pricing near-term earnings and revenue growth risk into the equity, but that haircut creates optionality if non-core franchises reaccelerate or integration synergies materialize. Expect payers and PBMs to use any momentary pricing pressure as leverage in contracts over the next 6–18 months, compressing realized prices faster than list-price moves; that dynamic disproportionately penalizes high-volume, margin-sensitive launches while leaving legacy specialty margins more intact.

Second-order winners include CDM/large-cap API suppliers and contract manufacturers that can redeploy capacity from mature GLP-1 lines to neuroscience and cardiometabolic programs; expect their book-to-bill to re-rate within 9–12 months as capacity bottlenecks normalize. Conversely, pure-play obesity/weight-loss developers without diversified franchises face an outsized funding and valuation hit, raising consolidation risk among mid- and small-caps in the next 12–24 months.

Key tail risks: (1) an extended pricing war that drives sustained 100–300 bps gross-margin erosion over 12 months; (2) integration execution that slips beyond 18 months with >$0.10 EPS dilution from amortization and one-time costs; (3) regulatory or formulary setbacks. Near-term catalysts that would reverse the negative sentiment are payer contract wins, clear synergy roadmaps with quantified savings within 9 months, or clinical readouts showing durable differentiation — any of which could flip the stock trajectory within a quarter or two.

A contrarian read is that the market is over-discounting durable free cash flow from non-launch franchises and under-weighting the optionality of successful neuroscience assets, meaning a disciplined buy-on-weakness approach captures asymmetric upside if execution meets conservative milestones.

Key Decisions for Investors

• Buy LLY on a >10% downside from current levels within the next 4–8 weeks; target +25% in 9–12 months, stop at -12% to limit event-driven downside (risk/reward ~2:1–3:1 assuming a recovery to mid-term guidance).
• Initiate a calendar/LEAP option structure: buy 18-month ATM calls and sell a 30% OTM call 6–9 months shorter to finance premium; cap max loss to premium paid and target 3:1 payoff if equity rallies >25% by the back-day expiry.
• Pair trade to neutralize macro beta: long LLY equity (or LEAPs) vs short the leading GLP-1 pure-play (or a large-cap GLP-1 leader) sized to net zero delta exposure; re-evaluate after each quarterly print to capture margin and mix divergence over 6–12 months.
• Selective event trade on CNTA: buy on a post-announcement >5% intraday gap-down or any 30% vol spike and sell into positive integration/data headlines within 12–24 months; this is high-volatility, high-upside (target 40–60%) with a tight 20% stop due to binary execution risk.